Company intelligence / Profile preview
Oncovita
Paris, Île-de-France, Franceoncovita.fr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Oncovita develops immunotherapeutic and prophylactic vaccines using a proprietary measles virus vector platform. Its lead candidate, MVdeltaC, has shown strong immunogenic oncolysis properties against several solid tumor types in preclinical models. The company secured €8 million funding at the end of 2023 to support GMP manufacturing and initiate first-in-human clinical trials. Additional candidates targeting HPV-induced cancers and infectious diseases are also under development.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Oncolytic viruses (measles virus-based)Therapeutic vaccinesProphylactic vaccines
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Institut Pasteur (joint laboratory for R&D)Unither Pharmaceuticals (vaccine formulation/manufacturing partnership)advanced discussions with a leading CDMO for manufacturing collaboration
Beyond the preview
Go deeper on Oncovita.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oncovita.